NCT00840853View on ClinicalTrials.gov

Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2031

Conditions
Acute Lymphoblastic Leukemia (ALL)Chronic Lymphocytic Leukemia (CLL)Non Hodgkin's Lymphoma
Interventions
GENETIC

CD19CAR/virus specific T cells

CD19CAR/virus specific T cells will be thawed and given by intravenous injection from day +30 post transplant.

DRUG

Benadryl and Tylenol

Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.

Trial Locations (2)

77030

Houston Methodist Hospital, Houston

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER

NCT00840853 - Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT | Biotech Hunter | Biotech Hunter